translation agency

Being Alive
MEDICAL UPDATE: CMV Retinitis Prophylaxis Trial Reopened for Enrollment at USC
presented by Mark Katz, MD and reported by Jim Stoecker
November 5, 1993
Being Alive 1993 Nov 5: 14

Dr. Fred Sattler of USC and the Rand Schrader (5P21) Clinic announced that a national study of a new drug, valaciclovir, which may prevent CMV retinitis, has been reopened for new enrollment. This study, known as ACTG 204, rapidly reached its initial quota of 700 people last winter. To speed the evaluation process for this drug, the size of the study has been increased from 700 to 1200 so that only one year will be needed for follow up, instead of the originally projected two years. USC has received 28 of the additional slots (and a few more are available at UCLA).

Valaciclovir seems to have the same safety profile as acyclovir; most people tolerate it well. The main disadvantage is that ACTG 204 participants have to take 18 pills per day. Since the placebo pills in the lot contain lactose, some bloating and loose stools have occurred in those who are lactose intolerant.

If you are interested and have less than 100 T cells and do not have lactose intolerance or major GI symptoms, call Diane Ramos at 213.343.8280 (or UCLA at 310.206.6414) for more details.